Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Dompé.

Expert Illustrations & Commentaries™: Visualizing Corneal Innervation, Pathophysiology, and Treatment Mechanisms in Neurotrophic Keratitis

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

This video-based program is designed for health care professionals to explore the diagnosis and treatment of neurotropic keratitis (NK) through a unique perspective, putting the patient voice front and center. A patient with NK will share her experiences. Expert faculty will share commentary on NK etiology, pathogenesis, clinical presentation, diagnostic approach, efficacy and safety data of available therapies, and best practices for treatment of NK.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Dompé.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward ophthalmologists, optometrists, and other health care professionals who would be involved in treating NK.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the pathophysiology of NK as related to corneal sensory innervation
Classify the stages of NK based on corneal signs
Apply appropriate patient assessments to provide prompt diagnosis of NK
Assess the effect of therapy on the NK disease process
Discuss safety and efficacy data for approved and traditionally used therapies for NK

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

Chair

Anthony J. Aldave, MD
Professor of Ophthalmology
Walton Li Chair in Cornea and Uveitis
Chief, Cornea and Uveitis Division
Director, Cornea and Refractive Surgery Fellowship Program
The Jules Stein Eye Institute
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosures: Consultant: Dompé; Speakers’ Bureau: Dompé

Faculty

Clara C. Chan, MD, FRCSC, FACS, DABO
Assistant Professor
Department of Ophthalmology & Vision Sciences
University of Toronto
Medical Director
Eye Bank of Canada
Toronto, Ontario, Canada

Disclosures: Grant/Research Support: Allergan, Bausch & Lomb, Shire, Novartis; Consultant: Aequus, Allergan, Labtician Théa, ZEISS, Santen, Novartis, Sun Pharma; Speaker’s Bureau: Allergan, Johnson & Johnson, Novartis, Labtician Théa; Stock/Shareholder: Pfizer.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.